Company news
Pmv Pharmaceuticals, Inc. (NASDAQ:PMVP) news
Pmv Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 5, 2026: PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Press releases & updates
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
October 4, 2026
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
October 5, 2026
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
September 8, 2026
PMV Pharma Announces Proposed Public Offering of Securities
August 31, 2026
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
August 31, 2026
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
August 30, 2026
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 14, 2026
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
May 12, 2026
PMV Pharmaceuticals Announces Board Chair Transition
April 22, 2026
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
March 5, 2026
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
February 26, 2026
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 12, 2025
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 24, 2025
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
September 10, 2025
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 7, 2025
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
May 23, 2025
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
May 9, 2025
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
March 3, 2025
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 6, 2024
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
October 22, 2024
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
August 7, 2024
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
May 8, 2024
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
March 26, 2024
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
February 28, 2024
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
January 17, 2024
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
January 4, 2024
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 8, 2023
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
October 11, 2023
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
October 10, 2023
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 8, 2023
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
May 9, 2023
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
February 28, 2023
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 7, 2022
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
November 3, 2022
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 8, 2022
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
July 17, 2022
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
June 6, 2022
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2022
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
May 9, 2022
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 28, 2022
PMV Pharma Announces Changes to its Board of Directors
January 5, 2022
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 11, 2021
PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
September 8, 2021
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 12, 2021
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
May 13, 2021
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
April 5, 2021
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 9, 2021
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
March 2, 2021